Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Executive Summary
Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer
You may also be interested in...
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy
Genentech Continues Pipeline Push After Rituxan Fizzles In PPMS
The failure of Genentech's Rituxan in a Phase II/III trial in primary progressive multiple sclerosis adds weight to the idea that B cells do not play a role in the disease and may cast doubt on rituximab's potential in lupus